Table 4.

Hepatobiliary cancer–related deaths during the last 5 years of the study (2013–2017, Sweden only) as opposed to the whole study period (1969–2017, Sweden only).

2013–20171969–2017
IBDPopulation comparatorsIBDPopulation comparators
n, IR (95% CI)n, IR (95% CI)HR (95% CI)n, IR (95% CI)n, IR (95% CI)HR (95% CI)
Ulcerative colitis
HCC12, 0.05 (0.030.08)107, 0.04 (0.030.05)1.16 (0.642.10)53, 0.06 (0.05–0.08)305, 0.04 (0.03–0.04)1.89 (1.41–2.53)
ICC31, 0.12 (0.080.17)72, 0.03 (0.020.03)4.43 (2.916.75)100, 0.12 (0.10–0.14)137, 0.02 (0.01–0.02)7.75 (5.98–10.0)
ECC22, 0.08 (0.050.13)67, 0.03 (0.020.03)3.39 (2.095.48)86, 0.10 (0.08–0.12)194, 0.02 (0.02–0.03)4.78 (3.70–6.16)
Crohn's disease
HCC8, 0.06 (0.030.11)54, 0.04 (0.030.05)1.57 (0.753.29)25, 0.05 (0.03–0.07)137, 0.03 (0.02–0.03)2.01 (1.31–3.08)
ICC9, 0.06 (0.030.12)36, 0.02 (0.020.03)2.71 (1.305.62)21, 0.04 (0.03–0.06)82, 0.02 (0.01–0.02)2.87 (1.78–4.64)
ECC6, 0.04 (0.020.09)25, 0.02 (0.010.03)2.56 (1.056.23)20, 0.04 (0.03–0.06)83, 0.02 (0.01–0.02)2.74 (1.68–4.46)
  • Abbreviations: IR, incidence rate; n, number.